Profitability Metrics

Gross Margin
85.44%
Operating Margin
134.75%
Net Margin
86.52%

Efficiency Metrics

Revenue per Expense Ratio
44,348,652.0
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
134.75%
Income Tax Rate
0.00%
EPS
0.5800000000

Balance Sheet Analysis

Current Ratio
-1.70
Cash Ratio
-1.81
Working Capital
$-391.38M
Debt to Equity
0.59
Debt to Assets
36.86%
Equity Ratio
62.42%

Cash Flow Analysis

Operating Cash Flow Ratio
183.10%
Free Cash Flow Ratio
183.10%
CapEx to Revenue
0.00%
Dividends Paid
$36.86M
Stock Buybacks
$10.81M
Total Shareholder Returns
$47.67M
Cash Position Change
13.07%

Key Takeaways (2024 FY)

  • Revenue declined by 24.065834987356%, indicating potential market challenges
  • Maintained positive net income growth despite revenue changes
  • Increased R&D investment by 100.00%

Detailed Growth Metrics

Core Performance

Revenue
-24.07%
Net Income
1,600.43%
EPS
1,630.34%
Operating Income
2,436.78%

Operational Efficiency

R&D Expenses
100.00%
SG&A Expenses
1.86%
Operating Cash Flow
-30.16%
Free Cash Flow
-30.16%

Balance Sheet Health

Assets
-3.09%
Debt
287,418.76%
Book Value per Share
0.06%
Inventory
0.00%

Shareholder Returns

Dividends per Share
-1.39%
Shares Outstanding
-1.54%

Long Term Trends

3Y Revenue/Share
-21.57%
5Y Revenue/Share
-27.52%
3Y Dividend/Share
-7.12%
5Y Dividend/Share
-8.52%